Business
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. (" Theralase®...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Rutherrin(R) Increases Efficacy of Chemotherapy for Lung CancerTORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation and or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin®, has demonstrated an ability to provide a significant enhancement of Cisplatin efficacy in chemotherapy resistant Non-Small Cell Lung Cancer (\"NSCLC\") in a preclinical animal model.Theralase® recently press released its latest research, using the well-established Lewis Lung Cancer (\"LLC1\") orthotopic model, representing NSCLC. In this model, mouse lungs are implanted with lung cancer cells, inducing these mice to develop very aggressive, fast growing and metastatic lung tumors.In further experimentation, mice were treated with Cisplatin (currently one of the most prescribed chemotherapy drugs for lung cancer) in a control group versus Cisplatin combined with Rutherrin® in an active group.The mice treated with Cisplatin and Rutherrin® demonstrated a significantly higher (p<0.001) enhancement of cisplatin efficacy and a significantly higher (p < 0.001) increase in overall mouse survival. This survival is analogous to a 1 year overall survival in humans and is significant due to the aggressiveness of the LLCI orthotopic model.As shown in Figure 1, the Kaplan-Meier Curve represents animal survival versus time in days. As can be seen, the combination of Cisplatin with Rutherrin® produced a highly significant increase in overall survival of mice treated versus those who were untreated or treated with Cisplatin only.Theralase® believes that this preclinical data could be even further improved with the addition of radiation or Metformin to activate Rutherrin®, while resident in NSCLC cells. Figure 1: Kaplan-Meier Curve Survival Analysis of Mice After Tumour Inoculation and Treatment with Cisplatin or a Combined Treatment of Rutherrin® and CisplatinDr. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® stated, \"Cisplatin-based therapy is one...